Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 5 of 79. Open to participants first (2,630), then studies with results posted, then the rest; newest registration first within each.
- Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial CarcinomaNot yet recruitingNCT07460245Phase 2
- Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatmentNot yet recruitingNCT07460206Phase 2
- A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCRecruitingNCT07459634Phase 2
- A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNot yet recruitingNCT07459543Phase 4
- Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCRecruitingNCT07459296Phase 3
- Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCRecruitingNCT07457528Phase 2
- Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast CancerRecruitingNCT07457359Phase 2
- Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell CarcinomasRecruitingNCT07455032Phase 1
- To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07454187Phase 1/2
- Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07454018Phase 2
- LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal CancerNot yet recruitingNCT07453875Phase 1
- QLS5132 Combination Therapy in Advanced Solid TumorsNot yet recruitingNCT07453394Phase 1/2
- Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCCRecruitingNCT07452601Phase 2
- An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLCRecruitingNCT07452003Not applicable
- Cadonilimab Combined With RT in LACC Patients Ineligible for CCRTNot yet recruitingNCT07450963Phase 2
- Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1Not yet recruitingNCT07450183Phase 2
- A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07449780Phase 3
- A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.RecruitingNCT07448831Phase 2
- Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal CancerRecruitingNCT07448142Phase 2
- FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal CancerNot yet recruitingNCT07446465Phase 4
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal CancerNot yet recruitingNCT07446387Phase 2
- THIO and Cadonilimab in Resectable Hepatocellular CarcinomaRecruitingNCT07446257Early Phase 1
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasRecruitingNCT07444619Phase 1
- A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung CancerRecruitingNCT07444437Phase 2
- Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLCNot yet recruitingNCT07438600Phase 2
- Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical StudyRecruitingNCT07437898Phase 2
- A Study of TAK-505 in Adults With Solid TumorsRecruitingNCT07436728Phase 1/2
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)RecruitingNCT07433673Phase 2
- Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLCNot yet recruitingNCT07432984Phase 2
- Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian CancerNot yet recruitingNCT07432594Phase 2
- A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICCNot yet recruitingNCT07432568Phase 2
- Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07432087Phase 3
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2RecruitingNCT07431281Phase 3
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingNCT07426484Phase 4
- ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal CancerRecruitingNCT07425054Phase 2
- Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in SloveniaRecruitingNCT07422779Not applicable
- A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCCRecruitingNCT07422753Phase 2
- Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent GlioblastomaNot yet recruitingNCT07422363Phase 1
- Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerRecruitingNCT07421700Phase 1/2
- Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNot yet recruitingNCT07420439Phase 2
- A Phase 1 Study of the Safety and Tolerability of CTX-10726RecruitingNCT07419841Phase 1
- Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaRecruitingNCT07418190Phase 2
- Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 AmplificationRecruitingNCT07417501Phase 2
- Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaRecruitingNCT07416890Phase 2
- PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLCRecruitingNCT07416058Phase 2
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingNCT07415031Phase 2
- Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT07413601Phase 2
- Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaRecruitingNCT07413354Phase 2
- Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerRecruitingNCT07412613Phase 3
- NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUCNot yet recruitingNCT07412171Phase 2
- Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung CancerRecruitingNCT07410975Phase 2
- EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid TumorsRecruitingNCT07410676Phase 1/2
- PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.RecruitingNCT07410520Phase 2
- Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant ChemotherapyNot yet recruitingNCT07410234Phase 2
- Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon CancerNot yet recruitingNCT07409844Phase 2
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruitingNCT07407920Phase 2
- Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLCRecruitingNCT07405190Phase 2
- Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT StudyRecruitingNCT07405086Phase 4
- 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory TumorsRecruitingNCT07404332Phase 1
- Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerNot yet recruitingNCT07403877Phase 2
- Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCCNot yet recruitingNCT07403435Phase 2
- Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCCRecruitingNCT07403136Phase 2
- Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After SurgeryRecruitingNCT07400302Phase 2
- Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCCNot yet recruitingNCT07400094Phase 2
- Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLCRecruitingNCT07398937Phase 2
- Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical StudyNot yet recruitingNCT07398560Phase 2
- Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal CancerRecruitingNCT07398326Phase 2
- Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCRecruitingNCT07397611Phase 2
- Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast CancerRecruitingNCT07396324Phase 2
- Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid TumorsNot yet recruitingNCT07396090Not applicable
- Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingNCT07394244Phase 2
- ctDNA-guided Treatment Decision-makingRecruitingNCT07394218Phase 2
- Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT07393555Phase 2
- A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT07393542Phase 3
- Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerRecruitingNCT07392892Phase 2/3
- A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.RecruitingNCT07392736Phase 1/2
- Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract CancerRecruitingNCT07392541Phase 1/2
- A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT07392320Phase 2
- A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabRecruitingNCT07391670Phase 1
- A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]RecruitingNCT07390383Phase 2
- Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07388836Phase 2
- Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07388758Phase 2
- Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)Not yet recruitingNCT07388550Phase 1
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialRecruitingNCT07388524Phase 3
- Adebrelimab Neoadjuvant Treatment for Resectable ESCCNot yet recruitingNCT07388095Not applicable
- Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor CemiplimabRecruitingNCT07387198Phase 2
- Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair DeficiencyNot yet recruitingNCT07385846Phase 1
- A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCRecruitingNCT07385001Phase 1/2
- QL1706 Plus Lenvatinib in Previously Treated Penile CancerRecruitingNCT07384416Phase 2
- Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung CancerNot yet recruitingNCT07383116Phase 3
- XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) PatientsNot yet recruitingNCT07381777Phase 2
- MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical TrialNot yet recruitingNCT07381699Phase 2
- PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLRecruitingNCT07380984Phase 2
- A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid TumorsRecruitingNCT07376707Phase 1
- A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCEnrolling by invitationNCT07376629Phase 2
- Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ AdenocarcinomaNot yet recruitingNCT07374250Phase 2
- Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal CarcinomaNot yet recruitingNCT07373990Phase 3
- Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III TrialNot yet recruitingNCT07371897Phase 3
- Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell CarcinomaRecruitingNCT07371611Phase 3
- Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory CanalRecruitingNCT07370337Phase 2